Theravance and GSK submit COPD combo for EU review

01/11/2013 | PharmaTimes (U.K.)

GlaxoSmithKline and Theravance filed an application with the European Medicines Agency seeking approval to market Anoro, their once-daily inhaler UMEC/VI, as a maintenance treatment for symptom relief in adult patients with chronic obstructive pulmonary disease. The drug is a combination of vilanterol, a long-acting beta agonist, and umeclidinium bromide, a long-acting muscarinic antagonist.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC